keyword
MENU ▼
Read by QxMD icon Read
search

Hepatocellular carcinoma with hepatic vein thrombosis

keyword
https://www.readbyqxmd.com/read/29735798/thrombosis-of-the-portal-venous-system-in-cirrhotic-vs-non-cirrhotic-patients
#1
Vania Cruz-Ramón, Paulina Chinchilla-López, Oscar Ramírez-Pérez, Nancy E Aguilar-Olivos, Luis F Alva-López, Ericka Fajardo-Ordoñez, Ileana Acevedo-Silva, Patrick G Northup, Nicolas Intagliata, Stephen H Caldwell, Guadalupe Ponciano-Rodríguez, Xingshun Qi, Nahum Méndez-Sánchez
INTRODUCTION AND AIM: Thrombosis is a vascular disorder of the liver often associated with significant morbidity and mortality. Cirrhosis is a predisposing factor for portal venous system thrombosis. The aim of this study is to determine differences between cirrhotics and non-cirrhotics that develop thrombosis in portal venous system and to evaluate if cirrhosis severity is related to the development of portal venous system thrombosis. MATERIAL AND METHODS: We studied patients diagnosed with portal venous system thrombosis using contrast-enhanced computed tomography scan and doppler ultrasound at Medica Sur Hospital from 2012 to 2017...
April 9, 2018: Annals of Hepatology
https://www.readbyqxmd.com/read/29657612/deal-a-death-blow-hcc-in-cirrhotics-thrombotic-complications-their-frequency-characteristics-and-risk-factors
#2
Khalid Mahmood, Iftikhar Haider Naqvi, Aamer Mahmood, Syed Muhammad, Noor Muhammad
Introduction: The hepatocellular carcinoma (HCC), being the commonest primary cancer, holds the sixth slot in the list of common cancers worldwide. Thrombotic complications in the form of portal vein tumour thrombosis (PVTT) and bland portal vein thrombosis with HCC are common with a bad prognosis. Aim: The study aims to determine the demographic, clinical, and biochemical parameters of HCC patients. The study also compares the clinical and biochemical parameters among patients having HCC with and without thrombotic complication...
2018: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/29575841/-clinical-application-of-ldlt-after-reconstruction-of-ivc-using-artificial-blood-vessel-in-the-treatment-of-hcc-beyond-milan-criteria
#3
B C Sun, G Q Li, X L Huang, J J Qin, X X Mu
Objective: To assess application of reconstruction of retrohepatic inferior vena cava using artificial blood vessel in right lobe living donor liver transplantation (LDLT) in the treatment of hepatocellular carcinoma (HCC) beyond Milan Criteria. Methods: The clinical data of 9 HCC patients who underwent right lobe liver transplantation after reconstruction of retrohepatic inferior vena cava using artificial blood vessel between June 2015 and Nov 2016 at Liver Transplantation Center of the First Affiliated Hospital of Nanjing Medical University were retrospectively analyzed...
March 23, 2018: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/29532323/outcome-of-transarterial-chemoembolization-in-egyptian-patients-with-hepatocellular-carcinoma-and-branch-portal-vein-thrombosis
#4
H Abdella, M K Shaker, Iman Fawzy Montasser, M Sobhi, H Aly, A Sayed, S Saleh, A El Dorry
BACKGROUND/AIM: Portal vein tumor thrombosis (PVTT) is a common complication in hepatocellular carcinoma (HCC) and it was considered a relative contraindication for transarterial chemoembolization (TACE) by many centers. This study aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response, and 1-year survival. METHODS: Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT underwent TACE...
March 2018: Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology
https://www.readbyqxmd.com/read/29498924/sirvenib-selective-internal-radiation-therapy-versus-sorafenib-in-asia-pacific-patients-with-hepatocellular-carcinoma
#5
Pierce K H Chow, Mihir Gandhi, Say-Beng Tan, Maung Win Khin, Ariunaa Khasbazar, Janus Ong, Su Pin Choo, Peng Chung Cheow, Chanisa Chotipanich, Kieron Lim, Laurentius A Lesmana, Tjakra W Manuaba, Boon Koon Yoong, Aloysius Raj, Chiong Soon Law, Ian H Y Cua, Rolley R Lobo, Catherine S C Teh, Yun Hwan Kim, Yun Won Jong, Ho-Seong Han, Si-Hyun Bae, Hyun-Ki Yoon, Rheun-Chuan Lee, Chien-Fu Hung, Cheng-Yuan Peng, Po-Chin Liang, Adam Bartlett, Kenneth Y Y Kok, Choon-Hua Thng, Albert Su-Chong Low, Anthony S W Goh, Kiang Hiong Tay, Richard H G Lo, Brian K P Goh, David C E Ng, Ganesh Lekurwale, Wei Ming Liew, Val Gebski, Kenneth S W Mak, Khee Chee Soo
Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods SIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (90 Y) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment...
March 2, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29428943/comparison-of-outcome-of-hepatic-arterial-infusion-chemotherapy-combined-with-radiotherapy-and-sorafenib-for-advanced-hepatocellular-carcinoma-patients-with-major-portal-vein-tumor-thrombosis
#6
COMPARATIVE STUDY
Kenichiro Kodama, Tomokazu Kawaoka, Hiroshi Aikata, Shinsuke Uchikawa, Yuno Nishida, Yuki Inagaki, Masahiro Hatooka, Kei Morio, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Keiichi Masaki, Yoji Honda, Nami Mori, Shintaro Takaki, Keiji Tsuji, Hirotaka Kohno, Hiroshi Kohno, Takashi Moriya, Michihiro Nonaka, Hideyuki Hyogo, Yasuyuki Aisaka, Tomoki Kimura, Yasushi Nagata, Kazuaki Chayama
OBJECTIVE: To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT). METHODS: This retrospective study included 108 HCC patients with PVTT of the main trunk or first branch and Child-Pugh ≤7. Sixty-eight received HAIC + RT and 40 received sorafenib. Patients were then assigned to the HAIC + RT group (n = 36) and the sorafenib group (n = 36) through case-control matching...
2018: Oncology
https://www.readbyqxmd.com/read/29394731/-a-case-of-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis-treated-successfully-with-multidisciplinary-therapy-including-preoperative-stereotactic-body-radiotherapy-sbrt
#7
Sadaaki Nishimura, Akira Tomokuni, Shogo Kobayashi, Kei Asukai, Hirofumi Akita, Hidenori Takahashi, Yoshitomo Yanagimoto, Yusuke Takahashi, Norikatsu Miyoshi, Keijiro Sugimura, Kazuyoshi Yamamoto, Takeshi Ohmori, Masayuki Ohue, Masahiko Yano, Masato Sakon
A 61-year-old man untreated with hepatitis C virus presented to our hospital.He was diagnosed advanced hepatocellular carcinoma(HCC)with portal vein tumor thrombosis(PVTT).The hazy tumor was located in the left lobe, and the tumor thrombus extended into the left portal vein.The patient received stereotactic body radiotherapy(SBRT, 48 Gy/4 Fr)for PVTT. The extended left lobectomy with thrombectomy was performed 12 days after SBRT.Resected specimen was diagnosed histopathologically as a poorly differentiated HCC, vp1, and no viable tumor cells in the tumor thrombosis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29379006/long-term-outcomes-of-ante-situm-resection-and-auto-transplantation-in-conventionally-unresectable-hepatocellular-carcinoma-a-single-center-experience
#8
Qifa Ye, Cheng Zeng, Yanfeng Wang, Yingzi Ming, Qiquan Wan, Shaojun Ye, Yan Xiong, Ling Li
BACKGROUND Ante-situm resection and auto-transplantation (ante-situm for short) provides a more aggressive approach to conventionally unresectable hepatocellular carcinoma (HCC). We described the long-term outcomes of patients with HCCs who underwent this technique. MATERIAL AND METHODS Between October 2005 and December 2016, we performed 23 ante-situm liver resections. We evaluated postoperative complications, 90-day mortality, recurrence, and long-term survival rates, and reviewed the literature on this topic...
January 30, 2018: Annals of Transplantation: Quarterly of the Polish Transplantation Society
https://www.readbyqxmd.com/read/29366520/clinical-significance-of-soluble-programmed-cell-death-ligand-1-spd-l1-in-hepatocellular-carcinoma-patients-treated-with-radiotherapy
#9
Hyun Ju Kim, Sangjoon Park, Kyoung-Jin Kim, Jinsil Seong
PURPOSE: To investigate the clinical implications of the soluble programmed cell death-ligand 1 (sPD-L1) level in hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT). MATERIALS/METHODS: HCC patients treated with RT between June 2011 and March 2015 were prospectively recruited and sPD-L1 levels were measured using an enzyme-linked immunosorbent assay. Blood samples were obtained at the RT start, RT end, and 1-month follow-up. The associations of the sPD-L1 level with the clinical features and outcomes were analyzed...
January 20, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29331342/development-of-a-prognostic-score-to-predict-response-to-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-invasion
#10
Carlo Spreafico, Carlo Sposito, Marta Vaiani, Tommaso Cascella, Sherrie Bhoori, Carlo Morosi, Rodolfo Lanocita, Raffaele Romito, Carlo Chiesa, Marco Maccauro, Alfonso Marchianò, Vincenzo Mazzaferro
BACKGROUND & AIMS: Yttrium-90 transarterial radioembolization (TARE) has shown promising efficacy in the treatment of patients with hepatocellular carcinoma (HCC), associated with portal vein tumor thrombus (PVTT). The aim of this study is to identify prognostic factors for survival in patients with HCC and PVTT undergoing TARE, and build a prognostic classification for these patients. METHODS: This is a single center retrospective study conducted over six years (2010-2015), on consecutive patients undergoing TARE...
January 10, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29327075/phase-ii-study-of-sorafenib-combined-with-concurrent-hepatic-arterial-infusion-of-oxaliplatin-5-fluorouracil-and-leucovorin-for-unresectable-hepatocellular-carcinoma-with-major-portal-vein-thrombosis
#11
Min-Ke He, Ru-Hai Zou, Qi-Jiong Li, Zhong-Guo Zhou, Jing-Xian Shen, Yong-Fa Zhang, Zi-Shan Yu, Li Xu, Ming Shi
BACKGROUND: Sorafenib is recommended for the first-line treatment of advanced hepatocellular carcinoma (HCC). However, the median progression-free survival (PFS) of patients with HCC and major portal vein tumor thrombosis treated with sorafenib monotherapy is no more than 3 months. A prospective single-arm phase II study was conducted to determine whether adding hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin to sorafenib could improve on these results...
May 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29258719/the-role-of-liver-resection-in-the-management-of-intermediate-and-advanced-stage-hepatocellular-carcinoma-a-systematic-review
#12
REVIEW
G K Glantzounis, A Paliouras, M-C Stylianidi, H Milionis, P Tzimas, D Roukos, G Pentheroudakis, E Felekouras
BACKGROUND: The ideal management for patients with intermediate and advanced stage hepatocellular carcinoma (HCC) is controversial. The main purpose of this systematic review is to examine the role of liver resection in patients with intermediate stage HCC (multinodular HCCs) and in advanced stage HCC [mainly patients with portal vein tumor thrombosis (PVTT)]. METHODS: A systematic search of the literature was performed in Pud Med and the Cochrane Library from 01...
February 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29234631/sorafenib-versus-hepatic-arterial-infusion-chemotherapy-as-initial-treatment-for-hepatocellular-carcinoma-with-advanced-portal-vein-tumor-thrombosis
#13
Michihisa Moriguchi, Takeshi Aramaki, Hideyuki Nishiofuku, Rui Sato, Koiku Asakura, Kanji Yamaguchi, Toshihiro Tanaka, Masahiro Endo, Yoshito Itoh
Objective: To investigate the validity of hepatic arterial infusion chemotherapy with low-dose 5-fluorouracil and cisplatin (LFP) versus sorafenib as first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (Vp3, Vp4). Patients and Methods: We retrospectively reviewed the cases of Child-Pugh A advanced HCC with Vp3 or Vp4 treated with LFP or sorafenib between October 2002 and December 2013. Results: There were 32 patients in the LFP group and 14 patients in the sorafenib group...
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29207378/characteristics-of-hepatocellular-carcinoma-aggressiveness-factors-in-turkish-patients
#14
Hikmet Akkiz, Brian I Carr, Kendal Yalçın K, Vito Guerra, Sedef Kuran, Engin Altıntaş, Oğuz Üsküdar, Ümit Karaoğullarından, Ayşegül Özakyol, Salih Tokmak, Mehmet Yücesoy, Halil İbrahim Bahçeci, Abdulalh Ülkü, Tolga Akçam, Kamil Yalçın Polat, Nazım Ekinci, Halis Şimşek, Necati Örmeci, Abdulalh Sonsuz, Mehmet Demir, Murat Kılıç, Ahmet Uygun, Tuğsan Ballı, Ali Demir, Burcu Arslan, Figen Doran
A large cohort of hepatocellular carcinoma (HCC) patients from several collaborating Turkish institutions were examined for the tumor parameters of maximum diameter (MTD), portal vein thrombosis (PVT), and α-fetoprotein (AFP) levels. A relationship was found between MTD and blood platelet levels. Patients with large ≥5 cm tumors who had normal platelet levels had significantly larger tumors, higher percent of PVT, and significantly lower blood total bilirubin and liver cirrhosis than similar ≥5 cm tumor patients having thrombocytopenia...
2018: Oncology
https://www.readbyqxmd.com/read/29145293/y-configuration-stent-combined-with-iodine-125-seeds-strand-for-the-treatment-of-hepatocellular-carcinoma-with-tumor-thrombosis-in-portal-vein-branches-a-case-report
#15
Tan Tan, Yudong Xiao, Shunke Zhou, Cong Ma, Zishu Zhang
RATIONALE: Currently, the treatment of hepatocellular carcinoma (HCC) associated with portal vein tumor thrombosis (PVTT) is a challenge. Percutaneous puncture endovascular placement of iodine-125 (I) seeds strand and stent is reported to treat HCC with tumor thrombus effectively. However, it is proved to be only suitable for the main portal vein (MPV) thrombus. PATIENT CONCERNS: A 42-year-old male patient was referred to our institution after experiencing right upper abdominal distention without abdominal pain, nausea, or vomiting for 2 weeks...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29137043/portal-vein-thrombosis-before-and-after-transjugular-intrahepatic-portosystemic-shunt-placement-an-observational-study-strobe-compliant
#16
Yue-Meng Wan, Yu-Hua Li, Hua-Mei Wu, Zhi-Yuan Xu, Ying Xu, Li-Hong Yang, Xi-Nan Wu, Jin-Hui Yang
Portal vein thrombosis (PVT) is common in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt (TIPS). This study had 3-fold aims: to assess risk factors for PVT; to determine the efficacy of anticoagulant therapy; to investigate the impact of PVT on clinical outcomes in TIPS-treated cirrhosis.Between June 2012 and February 2016, 126 TIPS-treated patients with cirrhosis were enrolled and studied prospectively. Enrolled patients were screened for PVT before TIPS and at 3, 6, 12, and 24 months post-TIPS...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29067511/safety-and-efficacy-of-transarterial-radioembolization-combined-with-chemoembolization-for-bilobar-hepatocellular-carcinoma-a-single-center-retrospective-study
#17
Joon Ho Kwon, Gyoung Min Kim, Kichang Han, Jong Yun Won, Man Deuk Kim, Do Yun Lee, Junhyung Lee, Woosun Choi, Yong Seek Kim, Do Young Kim, Kwang-Hyub Han
BACKGROUND: Radioembolization induced liver disease (REILD) is a possible sequela of transarterial radioembolization (TARE), particularly in cases of whole-liver treatment. To mitigate this problem, the safety and efficacy of combined transarterial chemoembolization (TACE) and TARE were evaluated for patients with bilobar hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Nineteen patients (mean age 60 years; range 27-82 years) treated for HCC between June 2012 and September 2014 were included in the analysis...
March 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28875374/yttrium-90-radioembolization-treatment-for-unresectable-hepatocellular-carcinoma-a-single-centre-prognostic-factors-analysis
#18
C Floridi, F Pesapane, S A Angileri, D De Palma, F Fontana, F Caspani, A Barile, A Del Sole, C Masciocchi, G Lucignani, G Carrafiello
The aim of this study was to evaluate the efficacy and the safety of Y90 radioembolization (Y90-RE) in patients with unresectable hepatocellular carcinoma (HCC) analysing our results and correlating them with independent prognostic factors for overall survival (OS) and for complications. Forty-three patients with advanced inoperable HCC including those with multiple bilobar lesions or portal vein thrombosis (PVT) treated with Y90-RE were reviewed. Treatment efficacy and safety were evaluated. Survival was calculated by the Kaplan-Meier method...
September 5, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28871990/transarterial-radioembolization-versus-concurrent-chemoradiation-therapy-for-locally-advanced-hepatocellular-carcinoma-a%C3%A2-propensity-score-matching-analysis
#19
COMPARATIVE STUDY
Jeong Eun Song, Kyu Sik Jung, Do Young Kim, Kijun Song, Jong Yun Won, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Jinsil Seong, Kwang-Hyub Han
PURPOSE: It is unclear whether the efficacy and safety of concurrent chemoradiation therapy (CCRT) and transarterial radioembolization (TARE) with (90)Y are comparable in patients with locally advanced hepatocellular carcinoma. METHODS AND MATERIALS: In total, 209 treatment-naive patients with stage B or C cancer according to the Barcelona Clinic Liver Cancer classification who were treated with TARE or CCRT were analyzed. Propensity scores were calculated and matched at a 1:1 ratio for TARE versus CCRT using age, tumor size, tumor number, portal vein thrombosis, and Barcelona Clinic Liver Cancer staging...
October 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28834778/outcomes-of-radioembolization-for-unresectable-hepatocellular-carcinoma-in-patients-with-marginal-functional-hepatic-reserve
#20
Derek M Biederman, Raghuram Posham, Raisa J Durrani, Joseph J Titano, Rahul S Patel, Nora E Tabori, Francis S Nowakowski, Aaron M Fischman, Robert A Lookstein, Edward Kim
PURPOSE: To evaluate the outcomes of radioembolization (RE) as a therapy for unresectable hepatocellular carcinoma (HCC) in patients with marginal functional hepatic reserve. METHODS: A retrospective review of 471 patients (1/2010-7/2015) treated with RE (Therasphere, BTG, UK) was performed. A total of 36 patients (mean age: 66.1±9.3, male: 86.1%) underwent therapy for HCC with a MELD≥15 (median: 16, range: 15-22). Baseline demographics of the study cohort were as follows: etiology (HCV: 26, 72...
January 2018: Clinical Imaging
keyword
keyword
72424
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"